Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (NASDAQ: INBS) announced its participation at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation, taking place in Kissimmee, Florida from May 28-31, 2025. INBS will showcase its Intelligent Fingerprinting Drug Testing Solution alongside U.S. distribution partner SMARTOX.

The company's innovative system uses fingerprint sweat to detect recent use of cannabis, cocaine, methamphetamine, and opiates, delivering results in under 10 minutes. Currently used in the U.S. for Forensic Use Only, INBS is pursuing FDA approval to enter the broader U.S. market this year. The company maintains over 450 active accounts across 24 countries, demonstrating strong global demand for its drug testing solutions.

Intelligent Bio Solutions (NASDAQ: INBS) successfully completed a large-scale workforce drug testing operation at Barcaldine Regional Council in remote Queensland, Australia, using its Intelligent Fingerprinting Drug Screening System. The company tested 160 employees in under 90 minutes, demonstrating significant efficiency compared to traditional testing methods.

The fingerprint-based system delivered rapid results in under 10 minutes per test, allowing the entire workforce to be cleared for duty before 8:00 a.m. The Council has now been trained for in-house random testing, with plans for continued workforce testing through INBS's on-site model. The company currently serves over 450 accounts across 24 countries, marking this successful deployment as a strategic expansion into regional and remote workforce testing markets.

Intelligent Bio Solutions (NASDAQ: INBS) reported significant growth in its global fingerprint drug testing operations. The company has surpassed 450 active accounts across 24 countries, adding 35 new accounts in fiscal Q3. INBS's Intelligent Fingerprinting Drug Screening System, which delivers results in under 10 minutes through sweat analysis, has expanded into multiple sectors including manufacturing, transport, logistics, engineering, and mining.

Key expansion milestones include entry into Europe's luxury marine sector, regional testing programs in Australia, adoption in Australia's waste and recycling sector, and penetration into Australian retail. The company's distributor network now spans 19 countries through 18 partners. INBS is also planning to introduce a collected testing service and preparing for entry into the U.S. market.

Intelligent Bio Solutions (NASDAQ: INBS) has launched three new localized websites in Arabic, Italian, and Spanish as part of its global expansion strategy. This digital expansion provides access to markets representing over 1.4 billion people across Europe, the Middle East, and Latin America.

The company's fingerprint sweat-based drug screening system, which provides results in under 10 minutes, currently serves over 400 active accounts in 19 countries. The Latin American drug screening market alone is projected to reach $1.1 billion by 2030. The multilingual rollout complements INBS' recent advancements in multilingual reader functionality and aims to strengthen distributor relationships and accelerate market penetration in non-English speaking regions.

Intelligent Bio Solutions (NASDAQ: INBS) has announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System, expanding its multilingual capabilities alongside English and Arabic. This strategic enhancement targets the growing Latin American drug screening market, projected to reach $1.1 billion by 2030.

The update significantly extends the system's accessibility across Spanish-speaking regions, particularly important as Spanish is the fourth most spoken language globally with over 500 million speakers and official status in more than 20 countries. The expansion is part of a broader multilingual upgrade aimed at reaching over 4 billion potential users worldwide.

The company currently serves over 400 accounts across 19 countries and is preparing to enter the U.S. market following its FDA 510(k) submission in December 2024. In Europe, Spain's drug testing market is expected to reach $368.4 million by 2030.

Intelligent Bio Solutions (NASDAQ: INBS) has integrated Arabic language support into its Intelligent Fingerprinting Drug Screening System, marking its second international language integration. This strategic move follows the company's early 2025 Middle East expansion plans through partnership with Ivy Diagnostics.

The Arabic integration targets approximately 450 million Arabic speakers across 25 countries, particularly focusing on safety-critical industries, law enforcement, and drug rehabilitation sectors. With the workplace drug testing market in Saudi Arabia projected to reach $64.5 million by 2030, this update enhances accessibility for Arabic-speaking organizations.

This development follows INBS's recent FDA 510(k) submission in December 2024 and planned U.S. market entry in 2025, supporting the company's global expansion strategy across North and South America, Europe, Asia Pacific, and the Middle East, building on its presence in 19 countries.

Intelligent Bio Solutions (NASDAQ: INBS) announced its gold sponsorship at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference, scheduled for April 1-4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs, will present the company's Intelligent Fingerprinting Drug Testing Solution on April 1.

The technology offers a portable, non-invasive drug screening method using fingerprint sweat, providing an alternative to traditional testing approaches. The company currently serves over 400 accounts across 19 countries in sectors including construction, transportation, mining, and manufacturing.

INBS is preparing to enter the U.S. drug screening market later this year, using the NDASA conference as a platform to engage with industry stakeholders and showcase their solution's relevance to the U.S. market.

Intelligent Bio Solutions (INBS) has expanded its fingerprint drug testing presence in Spain and Andorra through a strategic partnership with Detecto, a division of MTB Distribuciones Tecnologicas SL. The collaboration targets the Spanish drug testing market, projected to reach $448 million by 2030.

Major clients including Metro Barcelona and a large Rio Tinto-based mine currently require 1,000 drug testing cartridges monthly. The system has gained acceptance due to its non-invasive nature, easy collection process, and reduced maintenance costs through yearly calibration.

Detecto is expanding its focus to include law enforcement, rehabilitation, and maritime sectors, while seeing growth opportunities in ports, mining, and transportation. The partnership aims to leverage both companies' strengths to expand fingerprint sweat-based drug testing across various sectors.